Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.

Ankit Gupta, Herbert F Jelinek, Hayder Al-Aubaidy

Journal: Diabetes & metabolic syndrome 2018;11(3):225-230

PMID: 27884496

Full Text on Elsevier Science View on PubMed

Abstract

This study summarizes major work which investigated the roles of glucagon like peptide-1 (GLP-1) and its receptor (GLP-1R); the use of GLP-1-R agonists and dipeptidyl peptidase 4 inhibitor in the management of type 2 diabetes mellitus. It focuses on the recent therapeutic development which has occurred in this field, and also discusses the potential treatments which can be discovered and implemented in the near future to design an effective therapy for type 2 diabetes mellitus.

Address: School of Medicine, University of Tasmania, Hobart, Australia.; School of Community Health, Charles Sturt University, Albury, NSW, Australia.; School of Medicine, University of Tasmania, Hobart, Australia. Electronic address: [email protected].

DOI: 10.1016/j.dsx.2016.09.003

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetestype2.html

Other Literature Sources:

https://scite.ai/reports/27884496

Subscription / membership required

Full Text Sources:

MeSH Terms: Amino Acid Sequence, Diabetes Mellitus, Type 2, Disease Management, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists